Medetomidine is a potent non-opioid veterinary sedative now emerging as a dangerous adulterant in the illicit opioid supply, primarily fentanyl. A racemic mixture of levmedetomidine (l-isomer) and dexmedetomidine (d-isomer), it belongs to the same alpha-2 agonist class as xylazine and clonidine but is 200 to 300 times more potent than xylazine, with a longer duration of sedation and analgesia. Its d-isomer, dexmedetomidine (Precedex), is FDA-approved for short-term IV sedation and is used off-label for alcohol withdrawal and opioid detoxification.1 Beyond acute toxicity, medetomidine produces a withdrawal syndrome distinct from opioid withdrawal that can be life-threatening and refractory to standard protocols (see page 2).5
DEA forensic laboratory (NFLIS) data document a dramatic rise: 12 detections in 2021, 2,616 in 2024, and 8,391 in 2025, a more than 700-fold increase over four years. DEA toxicology surveillance identified 27 medetomidine-involved overdoses (4 fatal) since April 2023, with 96% co-containing fentanyl, and a cluster of 14 cases emerged in Chicago in May 2024.2
Medetomidine is not detected by standard immunoassay panels; definitive identification requires medetomidine-specific LC-MS/MS. Because the assay measures total medetomidine and does not differentiate the isomers, a positive could in principle reflect medical dexmedetomidine (for example, hospital IV sedation), so clinical context is required. Confirm with your laboratory which analytes are included, the detection method, and whether isomer differentiation is available.3 Order medetomidine-specific testing when unexplained bradycardia, profound sedation, or atypical hypertensive withdrawal accompanies suspected fentanyl exposure.
Confirms recent exposure. A positive LC-MS/MS result indicates recent medetomidine use, typically as an unlabeled fentanyl adulterant.
Absence of effect does not exclude it. Absence of clinical effect does not preclude recent exposure; interpret with timing and dose.
Does not change acute reversal. Naloxone remains appropriate for the opioid component; it will not reverse medetomidine's sedative or cardiovascular effects.
May be outside the window. The window is short (<24 h from dexmedetomidine data); a negative does not rule out earlier use.
Not on routine panels. Standard immunoassays and routine fentanyl panels do not include medetomidine unless requested.
Timing and cutoff. Absence may reflect timing of last use or levels below the cutoff.
Medetomidine analytes and pharmacokinetic notes.
| Metabolite | Clinical Significance |
|---|---|
| Medetomidine (total) | Racemic; the assay measures total drug and does not differentiate isomers. |
| Dexmedetomidine (d-isomer) | FDA-approved IV sedative (Precedex); provides the human PK reference (window <24 h). |
| Levmedetomidine (l-isomer) | No human PK data; urinary window not established. |